---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-002936"
form_type: "8-K"
ticker: "ONCO"
cik: "0001782107"
company_name: "Onconetix, Inc."
filed_at: "2023-01-17T23:59:59+00:00"
generated_at: "2026-06-20T14:50:29.758367+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Blue Water Vaccines appoints Timothy Ramdeen to board; Kimberly Murphy resigns

## Summary
- Kimberly Murphy resigned from Board, Nominating, Compensation, and Audit Committees effective Jan 13, 2023; no disagreement with company.
- Board appointed Tim Ramdeen, founder/managing partner of Dharma Capital Advisors, to replace Murphy.
- Ramdeen will chair Nominating Committee and serve on Compensation and Audit Committees.
- Ramdeen brings nearly a decade of private equity and hedge fund investing experience, including at Altium Capital and Sixth Borough Capital.

## SEC filing metadata
- accession: 0001213900-23-002936
- form_type: 8-K
- ticker: ONCO
- cik: 0001782107
- company_name: Onconetix, Inc.
- filed_at: 2023-01-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782107/000121390023002936/0001213900-23-002936-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782107/000121390023002936/ea171727-8k_bluewater.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-002936
- JSON: https://secwatch.observer/filing/0001213900-23-002936.json
- Plain text: https://secwatch.observer/filing/0001213900-23-002936.txt

## Key facts
- Executive change
  Kimberly Murphy resigned as Director at Onconetix, Inc..
  - Action: resigned
  - Role: Director
  source text: Effective as of January 13, 2023, Kimberly Murphy resigned as a member of the Board of Directors (the “Board”) of Blue Water Vaccines Inc. (the “Company”), as well as from her positions as chair of the of the Nominating and Corporate Governance Committee of the Board and as member each of the Compensation Committee and Audit Committee of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782107/000121390023002936/0001213900-23-002936-index.htm
- Executive change
  Tim Ramdeen was appointed as Director at Onconetix, Inc..
  - Action: appointed
  - Role: Director
  source text: Effective as of January 13, 2023, the Board appointed Tim Ramdeen to replace Ms. Murphy and serve as a member of the Board, chair of the Nominating and Corporate Governance Committee of the Board and a member each of the Compensation Committee and Audit Committee of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782107/000121390023002936/0001213900-23-002936-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.